Clinical Trial Detail

NCT ID NCT02402764
Title Phase 2 Trial of Selinexor (KPT-330) for Metastatic TNBC
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

Her2-receptor negative breast cancer

Therapies

Selinexor

Age Groups: adult

Additional content available in CKB BOOST